Engineered cell versus modified exosomes in cancer therapy
Rajib Dhar, Arikketh Devi
Abstract
Abstract Cancer therapeutic development is the most challenging domain in cancer. Cell‐based cancer therapeutics come up with promising effectiveness. This approach was also cell‐modified for better targeting efficiency development. Cell engineering‐based cancer therapeutic is a cutting‐edge method in cancer therapy. Due to complications of this process, cost and post‐treatment side effects, this phenomenon came into the question mark. In this scenario, extracellular vesicle (EVs) research introduces a cell‐free cancer therapeutic approach. In the therapeutic aspect most used EVs, come from stem cells, plants, and engineered cells. Among several EVs populations, Exosomes are the most used worldwide cell‐free therapeutic tool for ageing cancer. The most interesting facts about exosomes are the biocompatible, non‐immunoreactive, cross‐biological barrier, and non‐toxic (depending on the parental cell's nature). In this article, we are exploring modified exosomes (biological or chemical) that create a remarkable outcome in cancer therapeutic development compared to engineered cell‐based therapeutics. Hope, in the future, modified exosomes become an effective, affordable, and specific cancer‐targeting precision medicine.